Literature DB >> 18318437

Mortality attributable to cholestatic liver disease in the United States.

Flavia D Mendes1, W Ray Kim, Rachel Pedersen, Terry Therneau, Keith D Lindor.   

Abstract

UNLABELLED: In the past 2 decades, important advances have been made in the treatment of cholestatic liver diseases, including primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC). Whether these new therapies have had demonstrable impact on mortality on a population-wide scale has not been evaluated. This study describes the age-specific and sex-specific mortality rates from PBC and PSC in the United States between 1980 and 1998, based on the Multiple Cause of Death files. Age-specific and sex- specific mortality rates from PBC and PSC were calculated. The multivariable Poisson model was used to evaluate temporal changes in mortality rates. In 1998, the total age-adjusted and sex-adjusted PBC-related mortality rate was 0.24 per 100,000, and the age-adjusted and sex-adjusted PSC-related mortality rate was 0.23 per 100,000. During the observation period, PBC-related mortality significantly decreased over time in women younger than 65 years, and in men of all age groups, whereas in older women this number increased over time. PSC-related mortality remained essentially stable, except in men 65 years of age or older.
CONCLUSION: Since the early 1980s, significant changes in mortality from PBC have occurred. The most noticeable change was an increase in the age of death, which indicates prolongation of survival. These changes may be attributable to liver transplantation or ursodeoxycholic acid. In contrast, mortality from PSC remained largely unchanged, highlighting the need for more effective therapeutic strategies.

Entities:  

Mesh:

Year:  2008        PMID: 18318437     DOI: 10.1002/hep.22178

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  13 in total

1.  Current status of therapy in autoimmune liver disease.

Authors:  Gideon M Hirschfield; Nadya Al-Harthi; E Jenny Heathcote
Journal:  Therap Adv Gastroenterol       Date:  2009-01       Impact factor: 4.409

2.  38-year-old woman with abnormal liver enzymes and hyperlipidemia.

Authors:  Marina G Silveira; Keith D Lindor
Journal:  Mayo Clin Proc       Date:  2009-06       Impact factor: 7.616

Review 3.  Geoepidemiology and changing mortality in primary biliary cholangitis.

Authors:  Annarosa Floreani; Atsushi Tanaka; Christopher Bowlus; Merrill Eric Gershwin
Journal:  J Gastroenterol       Date:  2017-04-01       Impact factor: 7.527

Review 4.  Recurrence of autoimmune liver diseases after liver transplantation.

Authors:  Nabiha Faisal; Eberhard L Renner
Journal:  World J Hepatol       Date:  2015-12-18

Review 5.  Primary sclerosing cholangitis: overview and update.

Authors:  Flavia Mendes; Keith D Lindor
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-10-12       Impact factor: 46.802

6.  Increased cancer risk in a large population-based cohort of patients with primary biliary cirrhosis: follow-up for up to 36 years.

Authors:  Kirsten Boonstra; Robin Bokelaar; Paul H Stadhouders; Hans A Tuynman; Alexander C Poen; Karin M van Nieuwkerk; Ellen M Witteman; Dörte Hamann; Ben J Witteman; Ulrich Beuers; Cyriel Y Ponsioen
Journal:  Hepatol Int       Date:  2014-03-28       Impact factor: 6.047

Review 7.  Primary sclerosing cholangitis.

Authors:  Marina G Silveira; Keith D Lindor
Journal:  Can J Gastroenterol       Date:  2008-08       Impact factor: 3.522

8.  The MELD score predicts the short-term and overall survival after liver transplantation in patients with primary sclerosing cholangitis or autoimmune liver diseases.

Authors:  Katrin Hoffmann; Ulf Hinz; Norbert Hillebrand; Tom Ganten; Daniel Gotthardt; Thomas Longerich; Peter Schirmacher; Peter Schemmer
Journal:  Langenbecks Arch Surg       Date:  2014-08-09       Impact factor: 3.445

9.  Keratin variants are overrepresented in primary biliary cirrhosis and associate with disease severity.

Authors:  Bihui Zhong; Pavel Strnad; Carlo Selmi; Pietro Invernizzi; Guo-Zhong Tao; Angela Caleffi; Minhu Chen; Ilaria Bianchi; Mauro Podda; Antonello Pietrangelo; M Eric Gershwin; M Bishr Omary
Journal:  Hepatology       Date:  2009-08       Impact factor: 17.425

10.  Fibroblast Growth Factor 19 Activates the Unfolded Protein Response and Mitogen-Activated Protein Kinase Phosphorylation in H-69 Cholangiocyte Cells.

Authors:  Hannan A Qureshi; Jeffrey A Pearl; Kristy A Anderson; Richard M Green
Journal:  J Liver       Date:  2014-06-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.